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Abstract
It is critical to identify the cell of origin of cancer and the genes/proteins/transcriptional/epigenetic factors of that cell. 
Here, we review studies on head and neck cancer stem cells (CSC) in the hope of developing better understanding of 
their role highlighting their importance as novel drug targets. CSC model has introduced a hierarchical conceptual 
framework for the interpretation of intratumour heterogeneity within tumour. This, in turn, has culminated in a major 
paradigm shift in terms of how different types of cancers can be targeted for treatment. Several malignancies conform 
to the CSC model of tumour growth yet identification of CSC markers remains a profound challenge.
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Introduction
There are several prepositions that cancers arise 
from founder cells that are differentiated or an early 
progenitor cell or possibly the primary stem cell 
which undergoes aberrant reprogramming and result 
in cancer. Stem cells live the longest in the body and 
exhibit heterogeneity, self-renewal and slow cycling. 
Since these persist for the lifetime of an individual, 
these are more likely to accumulate mutations. 
Cancer cells with properties of stem cells are called 
cancer stem cells (CSCs) which have tumourigenic 
and metastatic capacity. Since CSCs are thought to 
give rise to tumours, understanding their properties, 
components and physiological roles are crucial.[1] The 
new hierarchical model of CSC has been introduced 
[Figure 1] as opposed to clonal evolution of cancer.[2] 
The ability to isolate these stem/progenitor cells by 
flow cytometry or magnetic beads and expanding them 
in culture flask gives us a powerful resource for high-
throughput screens that could yield potentially novel 
therapies for cancer treatment.
There is a mechanistic link between cancer and 
reprogramming of cell and involves a gain or loss of 
only a certain number of genes/proteins/transcriptional/
epigenetic factors that are dominant enough to induce 
reprogramming. This is supported by studies that 
suggested a single transcription factor could be all that is 
required to induce the reprogramming as long as it is the 
right factor for the right cell type.[3,4] The four transcription 
factors, OCT3/4 (octamer-binding transcription factor 3 
and 4), SOX-2 (sex-determining region Y), c-MYC and 
KLF4 oncogene (a gene which in certain circumstances 
can transform a cell into a tumour cell) shown by 
Takahashi[5] in their breakthrough work has also been 
reported to play oncogenic roles.
CSC Evidence in Head and Neck Cancer
Cancers of the head and neck squamous cell carcinomas 
(HNSCC) (six major sites: The oral cavity, pharynx 
[nasopharynx, oropharynx and hypopharynx], larynx, 
paranasal sinuses, salivary glands and thyroid gland) 
may arise from any of the lining membranes of the upper 
aerodigestive tract.
Existence of CSCs has been reported both in human 
HN tumours from patients and cell lines derived from 
primary tumours. After the first report on breast CSCs 
(CD44+CD24−) in 2003, growing evidence supported 
the concept that a subset of undifferentiated cells, with 
the ability to self-renewal, in several solid tumours 
such as brain (CD133+), colon (CD133+), prostate 
(CD44+), skin (CD20+) and pancreas (CD44+CD24+) is 
Correspondence: Saira Saleem, Basic Science Research Laboratory, 
Shaukat Khanum Memorial Cancer Hospital and Research Centre, 
Johar Town, Lahore 54000, Pakistan. Email: sairas@skm.org.pk
JOURNAL OF CANCER & ALLIED SPECIALTIES 2
J Cancer Allied Spec 2019;5(1):2 REVIEW ARTICLE 
generated, maintained and regrow into the bulk tumour 
population.[6-13] The cluster of differentiation (CD) is 
a protocol used for the identification and investigation 
of cell surface molecules present on cells. Prince et al. 
contributed the first report for the existence of CSCs in 
HN cancer with the use of CD44 as a marker for CSCs 
from primary tumours.[14] This study also performed 
the gold standard CSC test, the limiting dilution 
transplantation assay (LDA), in immune-compromised 
mice that determine the minimum number (5000) of 
CD44+ cells for tumour formation while CD44- cells failed 
to form tumours in the mice. Another study in the same 
year demonstrated that clonogenicity is restricted to a 
subpopulation of total cells within HNSCC each of which 
can generate populations with full range of heterogeneity 
present in parent cell line reflecting a stem cell pattern.[15] 
They found three different colonies, namely holoclones 
(compact, round and least differentiated), meroclones 
(scattered cells) and paraclones (more scattered cells 
having the highest degree of differentiation) from parent 
cell lines. Only holoclones resembling tumour contained 
CSCs while other two with more scattered cells were less 
likely to contain CSC [Figure 2]. Several observations 
made in these studies on HNSCC cell lines indicated 
that criteria sufficient to indicate persistence of stem cell 
pattern i.e., self-renewal, amplifying hierarchy and ability 
of differentiation are met.
Head and neck CSCs (HNCSCs) live in nearby vicinity 
of accompanying blood vessels known as the perivascular 
niche which provides a conducive environment for them to 
flourish and multiply.[17,18] Mutations attained overtime, in 
normal stem cells, empowers these cells for self-renewing 
property within an alternative niche which, in turn, 
becomes a proliferative hub for other mutant stem cells, 
hence, converting them to CSC. Alison et al. reported 
that self-renewal pathways (WNT, Hedgehog and Notch) 
impart vastly differentiating property to CSCs and make 
them unique for tumour progression.[19] A study reported 
that enriched CD133+ CSCs from four OSCC cell lines, 
PCI-4A, PCI-8, PCI-9A and PCI-13, showed reduced 
sensitivity to paclitaxel through ATP-binding cassette 
(ABC) drug transporters.[20]
Proteomics of Head and Neck Cancer
From a highly invasive oral cancer cell line UM1, 
non-adherent CSC-like cells (SOX2high OCT4high 
SOX9highCD44highHIF-1α lowPGK-1low) and adherent 
non-CSC UM1 cells were isolated. A lowly invasive 
UM2 oral cancer cell line was used as a control. Using 
Figure 1: Cancer heterogeneity models. (a) Hierarchical model of cancer stem cells (CSC). The CSC (in red) undergoes a division 
to give rise to a differentiated daughter cell (blue) and another CSC (red, self-renewal depicted by red arrow). The CSC by virtue 
of its infinite proliferative potential will continue to divide as above (dotted arrow). The differentiated cell may undergo a few 
divisions before terminal differentiation or senescence or cell death as the case may be. The CSC may undergo clonal evolution 
and acquire even greater tumourigenicity and/or chemoresistance and/or radioresistance (brown). Alternatively, a differentiated 
cell may dedifferentiate and acquire tumourigenicity (black arrow) and be converted to a CSC. (b) Clonal evolution model. Normal 
cells (blue) acquire mutations stochastically (yellow) and over successive divisions, and due to accrual of several mutations, these 
cells become transformed (red) and/or acquire chemo- and/or radio-resistance and can divide indefinitely (dotted arrow). Figure 
from Mitra et al., 2011[2]
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quantitative tandem mass tagging, a significant proteomic 
alteration between CSC-like and non-CSC UM1 cells was 
observed. In particular, transcriptional coactivator CBP 
(CREB-binding protein) and phosphorylated CREB-1 
(cyclic AMP response element-binding protein 1) were 
significantly upregulated in CSC-like UM1 cells versus 
non-CSC UM1 cells, suggesting that the CREB pathway is 
activated in the CSC-like cells.[21] Although there is ample 
evidence for the existence of CSCs, yet their isolation 
faces challenges because a definite marker has not been 
identified. Several cell surface receptors and intracellular 
proteins have been reported to be differently expressed 
between stem cells and differentiated mature cells. In HN 
cancer tissues, little progress has been made to mark CSCs. 
The widely accepted markers [Table 1] are also expressed 
by other basal layer cells which only allow for enrichment 
of CSCs instead of the isolation of pure cell population. 
The ambiguity of CSC markers is persisting despite large 
body of literature and information.[22] The suggested cell 
surface marker of CSCs in OSCC is hyaluronan receptor 
CD44;[14] however, there are contradictory reports on 
utility of CD44 with various isoforms as a marker for 
HNCSCs[23] and its role was questioned by a study in 
which both CD44+ and CD44− cells from squamospheres 
regenerated spheres from single cell suspension.[24] The 
expression of CD44 variants was associated with regional 
metastasis (CD44v3), perineural invasion (CD44v6) and 
radiation failure (CD44v10).[25] Cells expressing high 
CD29 and CD44 which can be used as markers to enrich 
CSCs in human SCC exhibiting molecular characteristics 
of EMT (a mechanism imparting stem-like properties to 
differentiated cells) suggest that CSC-associated pathways 
were involved in EMT. The first report of lung metastasis 
of HN cancer stem-like cells describing transcription 
factor SNAIL1 (zinc finger protein), oncogene BMI-1 
(polycomb complex protein) and oxidation enzyme ALDH 
Figure 2: Clonal morphology of human oral squamous cell carcinoma (OSCC)-derived cell line. An OSCC-derived cell line grown 
under serum-free conditions. Holoclones are characterised by round colony outlines and small, closely packed cells. Meroclones have 
larger and somewhat more flattened cells that remain in contact with each other in the central region but at the periphery of the colony 
have separated and acquired an ovoid outline. Paraclones consist largely of flattened scattered ovoid cells, few of which remain in 
contact. Figure modified from Costea et al., 2006[16]. Image courtesy Professor Dr. Daniela Costea (University of Bergen, Norway)
Table 1: Markers of HNCSCs
Marker References
CD44+ (CK5, CK14, BMI1) [14]
ALDHhigh (also+ve for CD44) [27]
OCT4, Nanog, CD117, Nestin, CD133, ABCG2 [28]
CD133+ [29]
CD44, OCT4, SOX2, SOX9 [21]
HNCSCs: Head and neck cancer stem cells
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(aldehyde dehydrogenase) as worst prognostic factors, 
strengthened the link between EMT and stemness in HN 
cancer.[26]
Oral cancer cell line proteome was studied by MALDI-TOF 
MS/MS and IPA analysis predicted that at least 18 
proteins including cell cycle regulator CLIC1 (chloride 
intracellular channel protein 1) and antigen processor 
proteasome activator complex subunit.[30] Two-dimensional 
electrophoresis and peptide mass fingerprinting detection of 
enolase-1 in the whole saliva were shown to be significantly 
higher for OSCC patients than for healthy individuals.[31] A 
low-molecular-weight candidate thioredoxin was detected 
by LC-MALDI-MSMS in oral fluids from OSCC patients 
and matched control patients, and the average level of 
thioredoxin in cancer samples was found to be about 
3 times higher than that in normal samples (P < 0.01).[32] 
In recent study, a statistically significant higher abundance 
demonstrated that complement factor b, C3 (complement 
component 3), glycoprotein C4B (C4-binding protein), 
serine protease inhibitor SERPINA1 (alpha-1-antitrypsin) 
and signal transduction glycoprotein leucine-rich-alpha-2 
glycoprotein are associated with the risk of developing 
OSCC.[33] A total of 26 proteins representing 12 unique 
gene products were identified hypopharyngeal squamous 
cell carcinoma by 2D-DIGE and MALDI-TOF/TOF 
MS. The upregulated proteins were AHSG (alpha-2-HS-
glycoprotein), complement C4-B, haemoglobin-binding 
liver protein Hp (haptoglobin), marker of inflammation 
C-reactive protein and copper-binding enzyme CP 
(ceruloplasmin), whereas the downregulated proteins 
were plasma protein ALB (serum albumin), component 
Table 2: Drugs which kill cancer stem cells
Drug Compound Structure Target Mode of action References
Cisplatin Cis‑diamminedichloroplatinum NFĸB – an 
inducible 
transcription 
factor present in 
an inactive form 
in the cytoplasm. 




it is activated 
and transported 
to the nucleus 
where it binds to 
DNA and activates 
transcription.
Nuclear transport 
of p16, recruitment 
of gigaxonin for the 
ubiquitination of 
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of the renin–angiotensin system angiotensinogen, 
SERPINA3 (alpha-1-antichymotrypsin), immunoglobulin 
component IGHG3 (Ig gamma-3 chain C region), blood 
clot component fibrinogen gamma chain, cholesterol 
transporter apolipoprotein A-I and immunoglobulin 
component and Ig kappa chain C region.
Current Treatment Modalities in Head and Neck 
Cancer and Protein-specific Drugs in Trial
This is imperative to switch from current non-specific 
treatments to personalised medicine. Chemoresistance 
due to the heterogeneous group of tumour cells is well-
reported impediment for failure of different therapeutic 
strategies. The challenges become multifold when 
disease spreads from its primary site. Even after the 
recent advancements in therapies for HN cancers, long-
term survival rate is still poor. Since decades platinum-
based agents (cisplatin) are being used as the first-line 
chemotherapeutic drugs for HN cancers, but their exact 
mechanism of action is not known. A p16-mediated 
cell cycle arrest with the use of cisplatin [Table 2] was 
found to cause downregulation of tumour suppressor 
genes and suppression of p16 has been linked to cisplatin 
resistance in HN cancer.[34] An iTRAQ-based MALDI-
MS proteomics study on four human HNSCC cell lines: 
Cisplatin-sensitive UM-SCC-23, UM-SCC-23-CDDPR 
with acquired cisplatin resistance, naturally cisplatin-
resistant UM-SCC-81B and UM-SCC-23/WR with 
acquired 5-fluorouracil resistance proposed α-Enolase 
as a true cisplatin chemoresistance factor of 13 proteins 
which were found to be associated with multidrug 
resistance.[35]
Bortezomib is the first therapeutic FDA approved 
proteosome inhibitor treating relapsed multiple myeloma 
and mantle cell lymphoma. In HN cancers, its solitary 
role has not been quite promising however, combining 
bortezomib with TRAIL (tumor necrosis factor related 
apoptosis inducing ligand) receptor agonists produced 
a synergistic cytotoxic effect in TRAIL-resistant HPV-
positive cells [Table 2].[36] A relatively new solid tumour 
treatment modality ALA-PDT (5-aminolevulinic 
acid-mediated photodynamic therapy) has been 
reported to reduce ALDH1 activity, CD44 positivity 
(widely accepted CSC markers), self-renewal and 
invasion of CSC in HN cancers resulting in enhanced 
chemosensitivity and apoptotic ability through NF-
kB/JNK signalling and decrease migration capacity 
of oral cancer cells by downregulation of FAK (focal 
adhesion kinase) and ERK (extracellular signal-regulated 
kinase).[37] One compound, salinomycin, reduces the 
proportion of CSCs by >100-fold relative to paclitaxel, 
a commonly used cancer chemotherapeutic drug.[38] The 
combination of cetuximab and the hedgehog inhibitor 
IPI-926, the proliferation inhibitors, is more active than 
either single agent in patient-derived xenograft models 
of HNSCC.[39]
Conclusions
We have presented an update in the area of head 
and neck cancer research highlighting a CSC model, 
identification of bona fide CSC marker is paramount. 
The high-throughput techniques in the field of 
proteomics can play a powerful role in achieving this 
goal which might change the course of medicine. 
A better understanding of cycling dynamics at molecular 
level within hyper- and hypo-proliferative cell 
populations after radio- and chemo-therapy is needed 
to better treat cancer. Thus, regardless of, whether 
the resistance is primary or acquired, digging into the 
molecular mechanisms involved and discovering, the 
definitive therapies targeting CSCs have undoubtedly 
become a pivotal issue in the treatment of human 
cancers and so far extraordinary efforts have been put 
into, to describe some incredible chemotherapeutic 
agents that selectively target CSCs by aiming the 
various pathways involved in regulation of these cells. 
Other salient mechanisms which can invalidate the 
therapeutic modalities include decreased intracellular 
drug accumulation, drug inactivation, perturbations in 
signal transduction pathways and apoptosis-/autophagy-
related chemoresistance.
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